

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 6th August 2025

FOI Ref No 29836

Requested Information:

- 1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.**
- 2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?**
 - Altuvoc
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)
 - Hemlibra in combination with any Factor VIII
 - NovoEight
 - NovoSeven RT
 - Nuwiq
 - Obizur
 - Refacto AF
 - Marstacimab
 - CEVENFACTA
 - Any other products
- 3. For patients treated with Advate in the last three months, please provide:**
 - The number of haemophilia A patients treated prophylactically
 - The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)
- 4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?**
 - Altuvoc
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)

- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Nuwiq
- Obizur
- Refacto AF
- Marstacimab
- CEVENFACTA
- Any other products

Response:

- 1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.**

81 registered patients

54 mild

8 moderate

19 severe

- 2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?**

- Altuvoco - **0**
- Advate - **5**
- Adynovi - **0**
- Elocta - **1**
- Esperoct - **3**
- Factor Eight Inhibitor Bypass Activity (FEIBA) - **0**
- Hemlibra (standalone)-**13**
- Hemlibra in combination with any Factor VIII - **0**
- NovoEight - **0**
- NovoSeven RT - **1**
- Nuwiq - **0**
- Obizur - **0**
- Refacto AF - **0**
- Marstacimab - **0**
- CEVENFACTA - **0**
- Any other products - **0**

- 3. For patients treated with Advate in the last three months, please provide:**
- The number of haemophilia A patients treated prophylactically- **1**
 - The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) - **4**
- 4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?**
- Altuvoco - **0**
 - Advate - **1**
 - Adynovi - **0**
 - Elocta - **0**
 - Esperoct - **2**
 - Factor Eight Inhibitor Bypass Activity (FEIBA) - **0**
 - Hemlibra (standalone) - **13**
 - Hemlibra in combination with any Factor VIII- **0**
 - NovoEight - **0**
 - NovoSeven RT - **0**
 - Nuwiq- **0**
 - Obizur - **0**
 - Refacto AF - **0**
 - Marstacimab- **0**
 - CEVENFACTA- **0**
 - Any other products - **0**

Attachment(s):

No attachment(s)

Date Response sent: 5th September 2025

